Coronary Artery Disease Oxidative Stress Angiography, Coronary Sodium-Glucose Transporter 2 Inhibitors Circulatory System
Conditions
Interventions
Experimental group: Single oral dose of empagliflozin 10 mg administered approximately 2 hours before elective coronary angiography, in addition to standard premedication (e.g., anxiolytics).
Control
Sponsors
General Hospital Slavonski Brod
Eligibility
Sex/Gender
All
Age
40 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. Scheduled for elective coronary angiography 2. Able to provide written informed consent
Exclusion criteria
Exclusion criteria: 1. Estimated glomerular filtration rate (eGFR) < 30 ml/min/1.73 m² 2. New York Heart Association (NYHA) class IV heart failure 3. Recent acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI) within the past 6 months 4. Active malignancy 5. Inflammatory or autoimmune disease 6. Chronic use of SGLT2 inhibitors 7. Diagnosed diabetes mellitus 8. Heart failure with reduced ejection fraction (HFrEF) 9. Life expectancy less than 12 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in oxidative stress levels, measured directly using Total Antioxidant Capacity (TAC) at baseline, 4, and 24h, and indirectly using a Comet assay at baseline, 4, and 24h, and N-glycan profiling at baseline and 24 hours after coronary angiography | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in biochemical markers, including serum creatinine, estimated glomerular filtration rate (eGFR), high-sensitivity cardiac troponin I (hs-TnI), and high-sensitivity C-reactive protein (hsCRP), were measured using standard biochemical methods at baseline and 24 hours after coronary angiography | — |
Countries
Croatia
Contacts
Public ContactKatica Cvitkusic Lukenda
Outcome results
None listed